Company Overview and News
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to report it has engaged Chuck Edwards P.Eng. as a technical advisor to assist the Company in planning and managing beneficiation (upgrading) and metallurgical studies and process design for the Ivana Uranium-Vanadium deposit and the Amarillo Grande project.
AMFW BSK BKUCF AMCBF AMFW CCJ
VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- AZARGA URANIUM CORP. (TSX:AZZ) (FRA:P8AA) (OTCMKTS:PWURF) (“Azarga Uranium”) and URZ ENERGY CORP. (TSX-V:URZ) (OTCQB:URZZF) (“URZ Energy”) are pleased to announce the execution of a definitive arrangement agreement (“Arrangement Agreement”) pursuant to which Azarga Uranium and URZ Energy will merge to form a new US-focused in-situ recovery (“ISR”) uranium development company (the “Transaction”).
PWURF AZZ EFR CCJ UUUU UUUU.WS
Fundamentally, the bull case for uranium is that Uranium prices have been depressed due to post-Fukushima negative sentiment towards nuclear power despite rising demand in emerging markets. Uranium miners have been trading near lows as cheaper crude oil prices subdued immediate pressure for energy importers to switch to alternatives. Nonetheless, the fundamental developments for uranium prices have been very positive and likely are the catalyst for a turnaround in uranium prices.
Thank you for standing by. This is the conference operator. Welcome to the Cameco Corporation First Quarter 2018 Results Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions] I would now like to turn the conference over to Rachelle Girard, Director of Investor Relations.
The following slide deck was published by Cameco Corporation in conjunction with their 2018 Q1 earnings call.
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
April 27 (Reuters) - Canada’s Cameco Corp reported a surprise profit for its first quarter on Friday, as the largest listed uranium producer benefited from higher prices and lower costs.
While the uranium spot price did bottom in November 2016, there has been very little upward momentum lately, which makes Ur-Energy one of the ideal and resilient investment candidates.
* CAMECO CORP - "WE EXPECT CASH FLOW IN 2018 TO BE SIMILAR TO 2017" Source text: [bit.ly/2I2XdBU] Further company coverage:
(Reuters) - Canada’s Cameco Corp (CCO.TO) (CCJ.N) posted a first-quarter profit on Friday compared with a loss a year ago as the uranium producer benefited from lower costs and higher prices of the commodity.
SASKATOON, Saskatchewan, April 27, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today reported its consolidated financial and operating results for the first quarter ended March 31, 2018 in accordance with International Financial Reporting Standards (IFRS).
15h - Asif
History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
as of ET